Clinical Trials Logo

Filter by:
NCT ID: NCT06228404 Recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC

Start date: March 3, 2024
Phase: Early Phase 1
Study type: Interventional

This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects.

NCT ID: NCT06228248 Recruiting - Clinical trials for Multidrug Resistant Bacterial Infection

Antibiotics Resistance Gene in Healthcare Workers

ARGH
Start date: January 18, 2024
Phase:
Study type: Observational [Patient Registry]

Multidrug resistant bacteria (MDR) pose a threat to the safety of patients worldwide. Drug resistant bacteria are commonly present in hospital environments and can cause infections, often leading to outbreaks within hospitals. Cross transmission through medical staff has been proven to be a significant cause of MDR bacterial transmission in hospitals. Although some studies have shown that the detection of gut drug-resistant bacteria in healthcare workers is similar to that in healthy individuals, these studies are limited to small sample sizes and detection methods. Here, the investigator characterize the differences between ARG colonization among healthcare workers and healthy populations through deep metagenomics.

NCT ID: NCT06228196 Recruiting - Vertigo Clinical Trials

Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China

Start date: January 8, 2024
Phase:
Study type: Observational

The main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (BPPV). Besides, the investigators aim to establish a database of BPPV based on multimodal magnetic resonance imaging data in the brain to identify high-risk patients with residual dizziness (RD) and systematically establish the comprehensive assessment system for the precise diagnosis, treatment and recovery of RD, optimize the tactics of BPPV management in China.

NCT ID: NCT06228183 Withdrawn - Stroke Clinical Trials

Effect of Intermittent Oro-esophageal Tube Feeding on Dysphagic Stroke Survivors

IOE-xinli
Start date: January 30, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore Clinical Effect of Intermittent Oro-esophageal Tube Feeding in Dysphagic Stroke Survivors. The main questions it aims to answer are: - Can Intermittent Oro-esophageal Tube Feeding improve psychological status in Dysphagic Stroke Survivors? - Can Intermittent Oro-esophageal Tube Feeding improve social interaction in Dysphagic Stroke Survivors? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Intermittent Oro-esophageal Tube Feeding as nutrition support and the control group will be given Nasogastric tube. The study lasts 21 days for each patient. Researchers will compare the Social Functioning Scale, Social Support Questionnaire, Patients Health Questionnaire-9, General Anxiety Disorder-7 to see if the Intermittent Oro-esophageal Tube Feeding can help improve the symptom.

NCT ID: NCT06228170 Withdrawn - Clinical trials for Traumatic Brain Injury

Efficacy of Stellate Ganglion Block in Traumatic Brain Injury Patients

SGB-TBI
Start date: January 30, 2024
Phase: N/A
Study type: Interventional

The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in Traumatic Brain Injury Patients. The main question it aims to answer are: Can stellate ganglion block improve the dysphagia and activities of daily living in Traumatic Brain Injury Patients. Traumatic Brain Injury Patients will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

NCT ID: NCT06228157 Withdrawn - Autistic Disorder Clinical Trials

Efficacy of Stellate Ganglion Block in Children With Autistic Disorder

SGB-gudu
Start date: February 5, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore efficacy of stellate ganglion block Children with Autistic Disorder. The main question it aims to answer is: Can stellate ganglion block improve the Autistic Disorder in children? Children with Autistic Disorder will be divided into the control group and experimental group evenly. All the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. The Childhood Autism Rating Scale of the two groups of patients before and after treatment are evaluated.

NCT ID: NCT06228131 Completed - Early Pregnancy Clinical Trials

Detection of hCG in Early Pregnancy Clinical Samples

Start date: August 1, 2023
Phase:
Study type: Observational [Patient Registry]

To evaluate the detection of hCG in the early pregnancy urine samples by Human chorionic gonadotropin (HCG) test system.

NCT ID: NCT06228118 Completed - Early Pregnancy Clinical Trials

Clinical Trail of the Lay User Study and Method Comparison Study of Human Chorionic Gonadotropin (HCG) Test System

Start date: August 4, 2023
Phase:
Study type: Observational

This clinical trial consisted of lay user study and method comparison study. Method comparison study: evaluate the clinical performance by comparing the results of new device and FDA cleared device (the comparator) tested on the same sample by professionals. Lay user study: evaluate the usability of by comparing the results of new device on the same sample tested by professionals and lay user, and by lay users complete the questionnaire.

NCT ID: NCT06228079 Not yet recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Start date: February 1, 2024
Phase: Phase 3
Study type: Interventional

Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial

NCT ID: NCT06227897 Not yet recruiting - Lung Cancer Clinical Trials

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

AERESA
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.